Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » News » The Future of Precision Oncology in Nuclear Medicine – Report

The Future of Precision Oncology in Nuclear Medicine – Report

  • June 16, 2022

Theranostics refers to a combined therapy and diagnostics approach to patient treatment. It involves the use of a diagnostic drug to first identify and label tumour cells – followed by the delivery of a therapeutic isotope (radioactive drug) to then kill the identified tumours.

Whilst used to diagnose and treat Neuroendocrine Tumours (NETs) for many years, researchers and biotech companies are making new discoveries in prostate, brain, kidney, ovarian cancer and neurological disorders.

In late 2021 NeuroEndocrine Cancer Australia and the National Theranostics Roundtable Committee brought together stakeholders from around Australia to discuss – The Future of Precision Oncology in Nuclear Medicine. Australia is in an enviable position with an expert nuclear specialist workforce, cutting edge research, new and emerging biotech companies, and manufacturing and sovereign capabilities through the Australian Nuclear and Science Organisation (ANSTO), although we need to ensure we future proof these competences, upscale, and most importantly have a HTA system that can adapt to new discoveries and technologies.

The report from this first National Theranositcs Roundtable summarises the many aspects presented at the event required for this precision medicine, hearing from researchers, clinicians, industry and from the Chairs of the MSAC, TGA and Cancer Australia.

The next steps are to put forward Theranostics as part of precision medicine considerations in the upcoming HTA review, as well as hold another forum concentrating on Theranostics Horizon Scanning and how Australia can maintain their capabilities in this fast-moving space.

Please below to read the report.

Download Report Here

Share this post

Recent posts

Sharon Rickard Completes Run Larapinta 2025!

August 18, 2025

Shane Kent Conquers the World’s Toughest Triathlon for Neuroendocrine Cancer Awareness

August 18, 2025

Turn Your Cans & Bottles into Support for NET Patients

August 12, 2025

National Patient Organisation Network (NPON)

July 24, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousCOVID-19 Information and Resources
NextCancer Nurses Society of Australia 24th Annual CongressNext

Related Posts

Sharon Rickard Completes Run Larapinta 2025!

A huge congratulations to Sharon Rickard, NET patient and proud CAG Member, who has just conquered the 2025 Run Larapinta Namatjira course — a gruelling

Shane Kent Conquers the World’s Toughest Triathlon for Neuroendocrine Cancer Awareness

What an incredible achievement!  Shane Kent has officially completed the world’s hardest triathlon – the Arch to Arc – in just 57 hours and 37

Turn Your Cans & Bottles into Support for NET Patients

From today, you can help the planet and support people living with neuroendocrine cancer by recycling your cans and bottles! NeuroEndocrine Cancer Australia (NECA) is

National Patient Organisation Network (NPON)

  National Patient Organisation Network (NPON) was held at the Brisbane Convention Centre on Thursday 24 July 2025 which had 50 attendees. Our CEO attended

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin